Donald G. Fell left the role of Director at Aspire Biopharma Holdings, Inc. As of November 14, 2026, Aspire Biopharma Holdings, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from January 13, 2026 to February 12, 2026, naming 2 departures (Form 8-K, February 12, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Aspire Biopharma Holdings, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Aspire Biopharma Holdings, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-01-13 to 2026-02-12. They name 2 people. Every row below is cited to the filing it comes from, and this page adds each new change as Aspire Biopharma Holdings, Inc. files it.
Also on the record for Aspire Biopharma Holdings, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 5, 2026 | Stake report, Schedule 13G, by Funk, Stephen P. | 5.8% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Highbridge Capital Management, LLC | — | 5%+ stakes | Source |
| August 10, 2026 | Stake report, Schedule 13G, by GARY SHIRINYAN | 7.7% of the class | 5%+ stakes | Source |
| August 6, 2026 | Stake report, Schedule 13G/A, by Lance Friedman | 7.92% of the class | 5%+ stakes | Source |
| July 2, 2026 | Stake report, Schedule 13G, by Rubenbauer Alois Ryan III | 5% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G, by Highbridge Capital Management, LLC | 5.2% of the class | 5%+ stakes | Source |
| May 13, 2026 | Stake report, Schedule 13G/A, by Ardsley Advisory Partners LP | — | 5%+ stakes | Source |
| April 10, 2026 | IPO filing, Form S-1/A | — | IPO filings | Source |
| February 17, 2026 | IPO filing, Form S-1 | — | IPO filings | Source |
| February 12, 2026 | Stake report, Schedule 13G, by Ardsley Advisory Partners LP | 7.76% of the class | 5%+ stakes | Source |
| December 3, 2025 | IPO filing, Form S-1 | — | IPO filings | Source |
| September 26, 2025 | IPO filing, Form S-1/A | — | IPO filings | Source |
Selling to them or working with them? See who runs Aspire Biopharma Holdings, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Aspire Biopharma Holdings, Inc. and the records around it.
Aspire Biopharma Holdings, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Who owns it
Companies that share a holder
- Highbridge Capital Management, LLC also filed stake reports on 83 other companies: Aeon Acquisition I Corp. (Aug 2026), Alpex Acquisition Corp (Aug 2026), Aperture AC (Aug 2026)
Watch Aspire Biopharma Holdings, Inc.
Get an email when Aspire Biopharma Holdings, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Aspire Biopharma Holdings, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Aspire Biopharma Holdings, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Aspire Biopharma Holdings, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 16 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-02-12 | Out | Director | 8-K, 2026-02-12 | ||
| 2026-01-13 | Out | 8-K, 2026-01-13 |
Why did they leave? What the filings say
For each named departures below, the sentence from the company's own filing that gives a reason, word for word. Where a filing gives none, it says so here; nothing is inferred.
- Donald G. Fell, Director (filed 2026-02-12):
Mr. Fell's decision to resign is not due to any disagreement with the Company, the Board of Directors, or any member of the Company's management.
- Surendra Ajjarapu (filed 2026-01-13):
Mr. Ajjarapu's decision to resign is not due to any disagreement with the Company, the Board of Directors, or any member of the Company's management.
Who leads Aspire Biopharma Holdings, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Donald G. Fell, departure reported (filed 2026-02-12). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on Aspire Biopharma Holdings, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Aspire Biopharma Holdings, Inc., with the record behind each one.
Find candidates like Director at Aspire Biopharma Holdings, Inc.Every change, in the filing's words
Departing: Donald G. Fell, Director
On February 6, 2026, Donald G. Fell resigned from the Aspire Biopharma Holdings, Inc.'s ("the Company") board of directors (the "Board").
- In connection with this transition, and the resignation of Suren Ajjarapu Philip Balatsos has been appointed to fill one of the vacancies on the Board of Directors left by the aforementioned resignations.
- Philip Balatsos Philip Balatsos is a Senior financial markets executive with experience in foreign exchange and emerging market sales and trading.
- He has a proven track record of driving revenue growth, expanding institutional client relationships, and building businesses across global markets.
- His experience spans bulge-bracket banks, international financial institutions, entrepreneurial ventures, and public company boards.
- He is presently holds a senior position at Oscar Gruss & Son Inc. in foreign exchange sales and trading.
- He previously served as vice president of foreign exchange and emerging markets rates sales and trading at XP Investments US LLC and was the director of foreign exchange hedge fund sales at Barclays Capital.
- He currently serves on the Board of Directors of Ciso Global, Inc. and Inspire Veterinary Partners, Inc. (OTCMKTS: IVPR), and served on the Board of Directors of Sadot Group Inc. from October 2019 through December 2023.
- He earned his Bachelor of Science in business administration from Skidmore College.
Departing: Surendra Ajjarapu
On January 7, 2026, Surendra Ajjarapu, a Director of Aspire Biopharma Holdings, Inc. (the "Company"), notified the Board of Directors of his intention to step down from the role of Director, effective immediately.
Tools for this story
Each opens in a new tab, filled in for Aspire Biopharma Holdings, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
